Patents Assigned to RA PHARMACEUTICALS, INC.
-
Patent number: 11965040Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: April 21, 2021Date of Patent: April 23, 2024Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 11932705Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: August 29, 2022Date of Patent: March 19, 2024Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11814445Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
-
Patent number: 11814444Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
-
Publication number: 20230303625Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: September 27, 2022Publication date: September 28, 2023Applicant: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11752190Abstract: The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.Type: GrantFiled: October 8, 2020Date of Patent: September 12, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
-
Patent number: 11723949Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.Type: GrantFiled: August 12, 2021Date of Patent: August 15, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
-
Patent number: 11707503Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: January 7, 2021Date of Patent: July 25, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
-
Patent number: 11535650Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: April 19, 2022Date of Patent: December 27, 2022Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 11530244Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11505575Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 22, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11123399Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.Type: GrantFiled: December 7, 2017Date of Patent: September 21, 2021Assignee: RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
-
Patent number: 11014965Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: January 2, 2020Date of Patent: May 25, 2021Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 10954287Abstract: The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.Type: GrantFiled: April 14, 2017Date of Patent: March 23, 2021Assignee: RA PHARMACEUTICALS, INC.Inventors: Kristopher Josephson, Zhong Ma, Yili Sun, Nathan Ezekiel Nims, Kathleen Seyb, Sylvia Tobe, Ping Ye, Douangsone D. Vadysirisack, Guo-Qing Tang, Douglas A. Treco
-
Patent number: 10918691Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: January 30, 2020Date of Patent: February 16, 2021Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
-
Patent number: 10835574Abstract: The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.Type: GrantFiled: December 7, 2016Date of Patent: November 17, 2020Assignee: RA PHARMACEUTICALS, INC.Inventors: Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
-
Patent number: 10588936Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: April 24, 2019Date of Patent: March 17, 2020Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
-
Patent number: 10562934Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: August 29, 2019Date of Patent: February 18, 2020Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Robert Paul Hammer
-
Patent number: 10435438Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: January 2, 2019Date of Patent: October 8, 2019Assignee: Ra Pharmaceuticals, Inc.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 10328115Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: February 26, 2018Date of Patent: June 25, 2019Assignee: Ra Pharmaceuticals, Inc.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter